leukemia

[Leukemia & Lymphoma] The authors investigated the prognostic significance of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) in t(8;21) acute myeloid leukemia (AML). A total of 47 t(8;21) AML patients were tested for TIM-3 expression by multi-parameter flow cytometry at diagnosis.

[Cell Reports] Researchers showed that acute myeloid leukemia cells secreted the stem cell growth factor R-spondin 2 (RSPO2) to promote their self-renewal and prevent cell differentiation.

[Cell Death & Disease] Functional assays demonstrated that knockdown of KCNQ1OT1 reduced acute promyelocytic leukemia cell proliferation and increased apoptosis. Mechanistically, KCNQ1OT1 bound to RNA binding protein FUS, and silencing either KCNQ1OT1 or FUS reduced the expression level and stability of MAP3K1 mRNA.

[Blood Advances] Scientists studied iron metabolism in patients with acute myeloid leukemia at diagnosis and explored the mechanisms involved using the syngeneic MLL-AF9–induced AML mouse model.

[Biosight Ltd. (Globe Newswire)] Biosight Ltd. announced the initiation of a Phase II trial to evaluate aspacytarabine, Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome or acute myeloid leukemia.

[Blood Cancer Journal] The authors found that interleukin-10 receptor (IL-10R) was overexpressed in most acute myeloid luekemia cells, and played an important role in promoting the stemness of leukemia cells.